Incredibly, only 6 percent of new pharmaceutical products ever recoup their development costs. Any other industry would simply cease production of such an unprofitable venture. But we don’t have that luxury. We need to change the way we do things and reduce resource-sapping redundancies. And that’s exactly what strategic data monitoring…
Amy Kissam, Executive Director, Integrated Clinical Processes, INC Research. INC Research is a global CRO providing the full range of Phase I to IV clinical development services across six continents through its global scale and scope, broad therapeutic expertise, and commitment to operational excellence using its proven Trusted Process. For more information, visit incresearch.com.